Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 6
Submit an article Journal homepage
170
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy

Rafael Madero-Marroquina Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAORCID Iconhttps://orcid.org/0009-0002-9243-2662View further author information
ORCID Icon,
Emily Dworkinb Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USAView further author information
,
Howard Weinera Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Caner Saygina Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Mariam T. Nawasa Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Michael W. Drazera Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Adam S. DuValla Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Satyajit Kosuria Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Michael J. Thirmana Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Olatoyosi Odenikea Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Wendy Stocka Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
,
Richard A. Larsona Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USAView further author information
&
Anand A. Patela Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0296-8686View further author information
ORCID Icon show all
Pages 864-867 | Received 22 Dec 2023, Accepted 25 Feb 2024, Published online: 05 Mar 2024
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

RM: no conflict of interest to disclose. ED: honoraria from AbbVie. HW: no conflicts of interest to disclose. CS: no conflicts of interest to disclose. MTN: no conflicts of interest to disclose. MWD: Scientific advisory board, Argenx. ASD: speaker for CE concepts. SK: no conflict of interest to disclose. MJT: has acted as a consultant or advisor to AbbVie; AstraZeneca; Celgene; Janssen; Pharmacyclics; Roche/Genentech. Research funding from AbbVie (Inst); Gilead Sciences; Janssen, Merck; Nurix; Pharmacyclics; Syndax; TG Therapeutics. OO: has acted as a consultant or advisor to AbbVie; Blueprint Medicines; BMS; Bristol-Myers Squibb/Celgene (Inst); Celgene; CTI; Impact Biomedicines; Kymera; Novartis; SERVIER; Taiho Pharmaceutical; Treadwell Therapeutics. Research funding from AbbVie (Inst); Agios (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Inst); Loxo (Inst); Novartis (Inst); NS Pharma (Inst); OncoTherapy Science (Inst). WS: advisor for Kura, Servier, Newave, and Asofarma. RAL: has acted as a consultant or advisor to AbbVie, Amgen, Ariad/Takeda, Astellas, Celgene/BMS, Curis, CVS/Caremark, Epizyme, Immunogen, Jazz Pharmaceuticals, Kling Biotherapeutics, MedPace, MorphoSys, Novartis, and Servier, and has received clinical research support to his institution from Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven/Gilead, Novartis, and Rafael Pharmaceuticals, and royalties from UpToDate. AAP: honoraria from AbbVie and BMS; research funding (institutional) from Pfizer, Kronos Bio.

Data availability statement

For original data, please contact [email protected].

Additional information

Funding

None.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.